Key Highlights

  • IBRX shares are trading up 9.50% to $8.55, against a prior close of $7.81.
  • The rebound follows a four-session losing streak that ended Monday.
  • The FDA expanded Anktiva's label to papillary-only NMIBC earlier this month.
  • Long-term data showed a 71% complete response rate.
  • The stock is up roughly 294% year to date.

Takeover Speculation Revives Interest After a Four-Session Slide

ImmunityBio (NASDAQ:IBRX) shares are trading up 9.50% to $8.55, rebounding from a four-session losing streak that ended with Monday's close at $7.81. A television market commentator described the stock as a promising speculative play and pointed to a wave of biotech takeovers, which renewed speculative interest. Volume is below average, based on market commentary.

Retail sentiment on social platforms has turned bearish, and the stock remains up roughly 294% year to date. Shares opened at $7.82, and the 52-week range runs from $1.95 to $12.43.

Anktiva Label Expansion and a 71% Complete Response Rate

Earlier this month, the FDA expanded the label for Anktiva to include papillary-only non-muscle-invasive bladder cancer, or NMIBC. Long-term data showed a 71% complete response rate.

ImmunityBio has a market cap of $9.06 billion and a loss of $0.97 per share, so no P/E ratio applies. The healthcare sector is little changed, with the State Street Health Care Select Sector SPDR ETF down 0.09%.

November Readout and Fourth-Quarter sBLA Filing Ahead

Investors are looking ahead to a final-analysis readout in November from a 366-patient trial of Anktiva plus BCG in BCG-naive bladder cancer. A planned fourth-quarter sBLA filing, short for supplemental biologics license application, is also on the calendar.

Final Analysis and sBLA Timeline Set the Next Catalysts

The net takeaway is that the move reflects speculation and positioning rather than a new company announcement. The November final analysis and the fourth-quarter sBLA filing are the next scheduled items to watch.